Please login to the form below

Not currently logged in
Email:
Password:

tacrolimus

This page shows the latest tacrolimus news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf

The Israeli generics manufacturer’s macrolide immunosuppressant medicinal Tacforius (tacrolimus) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) after demonstrating a “satisfactory quality”

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    diff. Alongside these launches the company has been moving into the oncology arena, adding to its legacy interest in urology from Yamanouchi and Fujisawa, and transplantation, where it has Prograf (tacrolimus)

  • Deal Watch November 2015 Deal Watch November 2015

    The deal includes Protopic (tacrolimus) for severe eczema treatment, skin creams Locoid and Locobase and acne therapy Zineryt (erythromycin/zinc acetate).

  • Pharma deals during October 2012 Pharma deals during October 2012

    that is in phase III. LCP-Tacro is a novel formulation of tacrolimus based on Veloxis' MeltDose technology, which enhances the bioavailability of compounds with low water solubility. ... 58. †Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence.

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    In transplantation, three years ago we launched Advagraf, a prolonged-release tacrolimus formulation, which offers the consistency of exposure so vital for transplant recipients.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics